Intellectual property group Allied Minds has cut funding for seven subsidiaries as part of a restructuring plan.

The company further plans to reallocate capital and management resources across the portfolio and pipeline in a bid to accelerate commercialisation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The subsidiaries are Biotectix, Cephalogics, CryoXtract, Novare Pharmaceuticals, Optio Labs, RF Biocidics and Tinnitus Treatment Solutions.

In aggregate, they represented $146.6m of Allied Minds’ group subsidiary ownership adjusted value (GSOAV) as of 30 June last year.

Allied Minds interim CEO Jill Smith said: “While many of the discontinued subsidiaries have demonstrated progress against technical milestones, the path to commercialisation is unlikely to yield appropriate financial returns.

See Also:

"While many of the discontinued subsidiaries have demonstrated progress against technical milestones, the path to commercialisation is unlikely to yield appropriate financial returns."

“The restructuring will result in a mark down to GSOAV. However, it places Allied Minds in a stronger position to capitalise on the exciting opportunities in front of us, and ultimately to deliver returns to shareholders over the medium term to longer term through accelerated commercialisation and monetisation, and portfolio growth.” 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Allied Minds plans to undertake a process to seek strategic alternatives, which may include sales or transfers of legal entities or assets, or liquidations, for these businesses.

Capital and management resources that will be unlocked as part of this process would be diverted to other companies and opportunities in the portfolio.

With the discontinuation of funding, the company is expecting to free up approximately $14m of capital spend budgeted for this year or about $9m net of a restructuring charge that is estimated at $4.7m, to be taken in the second quarter of this year.